Survival benefits of statins for primary prevention: a cohort study
- Submitting institution
-
The University of East Anglia
- Unit of assessment
- 11 - Computer Science and Informatics
- Output identifier
- 182586776
- Type
- D - Journal article
- DOI
-
10.1371/journal.pone.0166847
- Title of journal
- PLoS One
- Article number
- e0166847
- First page
- -
- Volume
- 11
- Issue
- 11
- ISSN
- 1932-6203
- Open access status
- Compliant
- Month of publication
- November
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
2
- Research group(s)
-
-
- Citation count
- 5
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Using electronic health records of people aged 60 and over in the UK, we investigated how a prescription of statins modified the risk of death. No longevity improvements were found for statin prescription by age 60 or with a low risk of a cardiac event, and significant improvements at ages above 65 with high risk ≥20%. In conclusion, the current recommended thresholds for statin therapy for primary prevention of cardiovascular disease may lead to overtreatment of younger people and those at low risk. The results further allowed to evaluate longevity improvement in the UK, published in The Actuary, August 2018.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -